SNAP-8: adverse events and evidence limits
The SNAP-8 listing names Acetyl Octapeptide-3 as lyophilized powder [1]. This octapeptide must remain distinct from the hexapeptide Argireline. The inspected 2024 primary paper explicitly gives the eight-residue SNAP-8 sequence [2].
That study tested a dissolving periocular microneedle patch containing SNAP-8, a vitamin C derivative and cyclic lysophosphatidic acid in hyaluronic acid. Of 24 participants, 21 completed the 28-day observation; the inspected Discussion reports no observed adverse effects [2].
This observation belongs to the complete multi-ingredient patch, rather than isolated octapeptide. It neither establishes reaction frequencies for the current powder nor verifies patch equivalence or systemic-administration safety. Selected methods, results and Discussion were read; Argireline findings cannot substitute for SNAP-8 evidence [1][2].
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Adverse effects | 24 participants (21 completed the 28-day observation); a dissolving periocular microneedle patch containing SNAP-8, a vitamin C derivative and cyclic lysophosphatidic acid | The authors reported no observed adverse effects; the observation belongs to the complete multi-ingredient patch rather than isolated SNAP-8 powder and does not establish reaction frequencies for it | [2] |
References
- Longeva (2026). SNAP-8 (Acetyl Octapeptide-3) https://longeva.bio/en/product/snap-8.
- Shin JY; Han D; Yoon KY; Jeong DH; Park YI (2024). Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. https://pubmed.ncbi.nlm.nih.gov/39082657/ doi:10.5021/ad.23.136.